Loading…
Caris Life Sciences, Inc. is projected to decline to $14.91 by 2027, a -3% move from its current price of $15.38. CAI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.83 | $15.39 | $15.97 | +0.06% |
| May 30 | $14.61 | $15.40 | $16.22 | +0.11% |
| May 31 | $14.45 | $15.41 | $16.43 | +0.17% |
| Jun 1 | $14.32 | $15.41 | $16.60 | +0.23% |
| Jun 2 | $14.20 | $15.42 | $16.75 | +0.28% |
| Jun 3 | $14.10 | $15.43 | $16.90 | +0.34% |
| Jun 4 | $14.00 | $15.44 | $17.03 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.00 | $15.44 | $17.03 | +0.40% |
| Week 2 | $13.50 | $15.50 | $17.80 | +0.79% |
| Week 3 | $13.14 | $15.56 | $18.44 | +1.19% |
| Week 4 | $12.85 | $15.62 | $19.00 | +1.59% |
| Week 5 | $12.60 | $15.69 | $19.52 | +1.99% |
| Week 6 | $12.39 | $15.75 | $20.01 | +2.40% |
| Week 7 | $12.20 | $15.81 | $20.48 | +2.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Caris Life Sciences, Inc. is an artificial intelligence TechBio company that provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Its molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients.
The company was founded in 2008 and is headquartered in Irving, Texas.
CAI is trading at $15.55 and has a market capitalization of $4.4B. It is ranked 1431 by market cap. The current technical picture shows bearish sentiment with RSI(14) at 40, and the stock sits below its SMA50 of $18.33 and SMA200 of $25.58.
Support is at $14.55 and resistance at $21.24. The 30-day price range spans from a low of $11.99 to a high of $20.16. The near-term outlook leans bearish, while the longer-term forecast signals meaningful upside growth potential.
A major floor 32.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 38.1% above — a clean break opens room to run.
A major ceiling 74.1% above — clearing it would confirm fresh momentum.
Key CAI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CAI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.62 | Sell | $15.49 | Sell |
| MA 10 | $15.26 | Buy | $15.74 | Sell |
| MA 20 | $16.67 | Sell | $16.52 | Sell |
| MA 50 | $18.21 | Sell | $18.09 | Sell |
| MA 100 | $20.42 | Sell | $20.23 | Sell |
| MA 200 | $25.44 | Sell | $23.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.12 | Neutral |
| Stoch RSI (14) | 35.02 | Neutral |
| CCI (20) | -56.17 | Neutral |
| Williams %R (14) | -84.31 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -4.77 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 15.69 | Buy |
| TRIX (15) | -0.78 | Sell |
| Awesome (5,34) | -2.42 | Sell |
| Ultimate (7,14,28) | 53.83 | Neutral |
| Momentum (10) | -1.38 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 15.72 | Sell |
| ADX (14) | 18.21 | Neutral |
| ATR (14) | 0.61 | Info |
The 30-day picture is bearish. The RSI(14) is 40, indicating mild downside pressure. The price is trading below the 50-day moving average of $18.33 and the 200-day moving average of $25.58, which reinforces the cautious near-term view. Key levels to watch are support at $14.55 and resistance at $21.24, with the 30-day range between $11.99 and $20.16.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.55 | $15.38 | $21.07 | 0% | Neutral | |
| $10.86 | $14.91 | $22.11 | -3% | Neutral | |
| $10.91 | $15.81 | $24.86 | +3% | Neutral | |
| $11.13 | $16.92 | $27.84 | +10% | Neutral | |
| $12.06 | $19.14 | $32.70 | +24% | Bullish | |
| $13.95 | $23.04 | $40.66 | +50% | Bullish | |
| $12.96 | $22.24 | $40.41 | +45% | Bullish | |
| $11.65 | $20.74 | $38.67 | +35% | Bullish | |
| $12.22 | $22.54 | $43.04 | +47% | Bullish | |
| $11.25 | $21.48 | $41.94 | +40% | Bullish | |
| $14.98 | $33.29 | $71.13 | +116% | Bullish | |
| $24.15 | $53.67 | $123.45 | +249% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $14.55 | $15.38 | $18.21 | +0.00% |
| June 2026 | $13.03 | $15.59 | $19.29 | +1.36% |
| July 2026 | $13.32 | $16.19 | $20.53 | +3.87% |
| August 2026 | $12.92 | $15.89 | $20.51 | -1.86% |
| September 2026 | $12.36 | $15.36 | $20.13 | -3.32% |
| October 2026 | $12.50 | $15.69 | $20.83 | +2.16% |
| November 2026 | $12.62 | $15.97 | $21.45 | +1.77% |
| December 2026 | $12.16 | $15.52 | $21.07 | -2.82% |
Click any year to see its month-by-month CAI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CAI price prediction for 2026 points to an average of $15.38 (low $14.55, high $21.07) — a potential gain of 0% on today's $15.38. Price action looks broadly range-bound.
In 2027, CAI is projected to trade between $10.86 and $22.11, averaging $14.91 — a potential decline of -3% from today's $15.38. That is -3% versus the projected 2026 average. A consolidation phase looks the most probable path here.
Caris Life Sciences, Inc.'s 2028 outlook centres on $15.81, within a $10.91 to $24.86 range. That is up +6% on the projected 2027 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2029, CAI could reach as high as $27.84, with a base case around $16.92 and support toward $11.13 — roughly +10% from $15.38. A consolidation phase looks the most probable path here.
Expect CAI to range from $12.06 to $32.70 through 2030. The $19.14 average target implies a +24% move from current prices. That is up +13% on the projected 2029 average. Momentum favours further upside here.
The CAI price prediction for 2031 points to an average of $23.04 (low $13.95, high $40.66) — a potential gain of +50% on today's $15.38. Buyers look set to stay in control over this stretch.
In 2032, CAI is projected to trade between $12.96 and $40.41, averaging $22.24 — a potential gain of +45% from today's $15.38. That is -3% versus the projected 2031 average. Momentum favours further upside here.
Caris Life Sciences, Inc.'s 2033 outlook centres on $20.74, within a $11.65 to $38.67 range. That is -7% versus the projected 2032 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CAI could reach as high as $43.04, with a base case around $22.54 and support toward $12.22 — roughly +47% from $15.38. Momentum favours further upside here.
Expect CAI to range from $11.25 to $41.94 through 2035. The $21.48 average target implies a +40% move from current prices. That is -5% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The CAI price prediction for 2040 points to an average of $33.29 (low $14.98, high $71.13) — a potential gain of +116% on today's $15.38. Momentum favours further upside here.
In 2050, CAI is projected to trade between $24.15 and $123.45, averaging $53.67 — a potential gain of +249% from today's $15.38. That is up +61% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CAI today (≈ 65.019506 CAI) could be worth
$3,489.91
+$2,489.91 (+249%) by 2050 · US Dollar
Based on the average projected CAI price of $53.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CAIwould be worth at today's price.
$1,000 invested in CAI on Jun 18, 2025 (≈ 35.714286 CAI) would be worth
$549.29
-$450.71 (-45.1%) today · 0.55× · US Dollar
Based on a CAI entry price of $28 vs. today's $15.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.7 | $979.62 | -2.0% |
| 1 month ago | $19.93 | $771.7 | -22.8% |
| 3 months ago | $19.24 | $799.38 | -20.1% |
| 6 months ago | $25.53 | $602.43 | -39.8% |
| All time ago | $28 | $549.29 | -45.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CAI forecast.
Our base-case forecast reaches $31.00 around 2040.
Implied market cap at $31.00: $8.76B
The year-by-year forecast shows a path from 2026 to 2050 with rising averages and upside potential. The 2026 forecast lists min $14.55, avg $15.55, max $21.47, with ROI 0 and NEUTRAL sentiment; by 2030 the avg is $19.90 (min $12.20, max $34.77) and ROI 28 with a BULLISH sentiment. The sequence continues through 2031–2035 with averages in the low to mid-20s and solid bullish momentum (2031 avg $23.82, 2032 $22.78, 2033 $21.31, 2034 $23.13, 2035 $21.93).
By 2040, the avg climbs to $34.39 (min $15.48, max $75.84) with ROI 121.2 and BULLISH sentiment, and by 2050 the avg is $55.90 (min $25.15, max $128.57) with ROI 259.5 and BULLISH sentiment. These figures point to a long-run upside, balanced by near-term volatility, and should be viewed as estimates rather than guarantees.
Tap a question to reveal the answer.
min $12.20, avg $19.90, max $34.77; ROI 28; sentiment BULLISH.
Near-term numbers show a neutral stance, with 2026 avg $15.55 and ROI 0; the forecast then turns bullish in the 2030s, with 2030 avg $19.90 and higher by 2040 and 2050, indicating upside potential but with risk and uncertainty.
Yes. The 2040 max is $75.84 and the 2050 max is $128.57, so a price of $50 is within the provided forward guidance.
Current price $15.55; market cap $4.4B.
Sentiment BEARISH; RSI14 is 40; SMA50 is $18.33; SMA200 is $25.58; support is $14.55 and resistance is $21.24; 30-day range is $11.99 to $20.16.
Caris Life Sciences, Inc. Community Discussion
0Share your Caris Life Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.